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in-person instruction on at-home knee exercise. The primary outcome
measure was a composite score on the Western Ontario McMaster
University Osteoarthritis Index (WOMAC; 100 points), which assessed
knee pain, function and stiffness on a per subject basis. The secondary
outcome was the Knee Pain Scale (KPS) which assessed knee pain severity
and frequency on a per knee basis; both were done at baseline, 5, 9
12, 26 and 52 weeks. Procedure-related opioid medication use, subject
satisfaction and adverse events were also assessed.
Results: Analysis was by intention to treat. No signiﬁcant baseline
differences existed between the groups in age, gender, pain duration,
body mass index or WOMAC scores. 89 subjects (57±8.3 years old,
59 female) with moderate to severe KOA received an average of 4.3±0.7
prolotherapy injection sessions over a 17-week treatment period. All
groups reported improved composite WOMAC scores compared to
baseline status (p < 0.01) at 52 weeks. However, WOMAC scores for
prolotherapy subjects, adjusted for gender, age and body mass index
showed signiﬁcantly greater improvement onWOMAC score at 52 weeks;
15.32±3.52 points for prolotherapy compared to 7.68±3.41 points for
saline injection (p < 0.05) and 8.25±3.33 points for exercise (p< 0.05).
The improvement by prolotherapy subjects exceeded minimal clinical
important difference. KPS scores of prolotherapy subjects showed similar
improvement per injected knee compared to baseline status (p < 0.001)
and controls (p < 0.05). Prescribed post-procedure opioid medication
resulted in rapid diminution of prolotherapy injection pain. Satisfaction
with prolotherapy was high and there were no adverse events.
Conclusions: Prolotherapy resulted in safe, signiﬁcant, sustained
improvement of pain, function and stiffness scores compared to blinded
saline injections and at-home exercises in knee osteoarthritis.
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Purpose: No approved disease-modifying OA drugs (DMOAD) are
available. Use of a chondrocyte-targeted growth factor is a promising
approach with the potential to induce chondrocyte proliferation, increase
matrix production and promote cartilage repair. This Phase I study
evaluated the local and systemic acute safety of recombinant human
ﬁbroblast growth factor 18 (rhFGF18) intraarticular (i.a.) injection,
after single ascending dose (SAD) and multiple ascending dose (MAD)
regimens in candidates for total knee replacement (TKR) surgery. As
secondary objectives, effects of rhFGF18 on systemic biomarkers and
exposure were evaluated. Tertiary objectives were to assess: effect of
rhFGF18 on knee cartilage in selected regions of interest by MRI and
X-ray; cartilage structure and absence/presence of cartilage proliferation
from samples taken during TKR surgery; effect of rhFGF18 on OA
symptoms in the target knee. An exploratory objective was to evaluate
biomechanical properties of cartilage taken during TKR surgery.
Methods: Eligible patients were ≥40y with primary femorotibial knee
OA, who were candidates for TKR surgery (planned ≥2 weeks after
anticipated last injection of study drug); stable oral OA treatment was
permitted. Patients received rhFGF18 or placebo, randomized 3:1 per
cohort, injected i.a. into the target knee once (SAD) or once weekly for
3 weeks (MAD). SAD cohorts received 3mg, 10mg, 30mg, 100mg or 300mg;
MAD cohorts received 10mg, 30mg, 100mg, 300mg or highest tolerated
dose. Follow-up and safety reviews occurred before each dose escalation.
All subjects had ﬁnal review 24 weeks after ﬁrst injection. Unconﬁned
compression testing (dynamic and equilibrium modulus) and histological
analysis (modiﬁed Mankin scoring) were conducted for cartilage taken
during TKR surgery.
Results: In SAD cohorts, 25 patients received rhFGF18; 8 received
placebo. In MAD cohorts, 30 patients received rhFGF18; 10 received
placebo. Age range 48.5–87.1 y; BMI range 21.1–46.8 kg/m2. No
local/systemic acute safety concerns emerged, no subjects discontinued
treatment prematurely, no adverse events (AE) led to discontinuation.
Two deaths were reported: 1 patient (MAD 30mg) died of pulmonary
embolism 2 days after TKR surgery (considered likely to be unrelated to
study drug); 1 patient (MAD placebo) died from myocardial infarction
3 months after his last dose of study drug (considered unrelated
to study drug). No pattern was evident among the 8 other serious
AE (all considered unrelated to study drug). Acute inﬂammatory
reactions were slightly more common in 300mg rhFGF18-treated groups.
Treatment emergent AE did not increase in treatment vs. placebo groups.
No systemic exposure to rhFGF18 or antibodies against FGF18 were
detected. Systemic biomarkers of cartilage and bone metabolism, and
inﬂammation, showed no systemic effect of rhFGF18. Although the study
was not designed to demonstrate efﬁcacy, cartilage samples obtained
during TKR surgery suggested chondrocyte proliferation, improved
histological grading and improvement in biomechanical properties after
rhFGF18. In the 30 patients evaluated with MRI there was a suggestion
of increased cartilage volume, especially in the medial femorotibial
compartment. No changes were seen on X-ray. Improvement of OA
symptoms occurred in both placebo and rhFGF18-treated groups.
Conclusions: These Phase I results suggest no local or systemic acute
safety concerns with rhFGF18 i.a. single or multiple injections. The
proportion of patients experiencing ≥1 AE was not increased in rhFGF18
groups. No systemic exposure was detected after injection. Cartilage
samples obtained during TKR surgery suggest that rhFGF18 elicits an
anabolic response in late-stage OA. MRI ﬁndings showed a positive trend,
although longer observation with more patients is required to conﬁrm
drug effects. These results are encouraging for further investigation of
rhFGF18 as a potential DMOAD.
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Purpose: Iron may be a contributing risk factor for osteoarthritis (OA)
development – increased iron is found in OA synovial ﬂuid and is
cytotoxic towards chondrocytes. Additionally, patients with hereditary
hemochromatosis develop an OA phenotype that is associated with
higher ferritin levels. We examined the hypothesis that serum ferritin
is elevated in patients with knee OA and that levels of ferritin correlate
with OA severity.
Methods: The study included 150 patients with symptomatic knee OA
(patients were diagnosed by ACR criteria with a WOMAC score >125)
and 21 controls who were enrolled in a 2 year longitudinal study.
Exclusion criteria were steroid use, inﬂammatory arthritis, infection,
diabetes, hepatic/renal disease, or heart failure. Baseline clinical (age,
gender, BMI, WOMAC pain score) and radiographic characteristics (KL
score) were obtained. Cross sectional peripheral blood samples were
analyzed for serum ferritin by ELISA. Plasma PGE2 and COMP fragments
were measured by ELISA and PCR based HFE genotyping performed on
patients and controls. Statistical analysis included ANOVA and student’s
t-test.
Results: Ferritin was measured in 129 OA patients with mean age
65 years (35% men), BMI 26.5 and, in those who had radiographic scoring,
KL score 0–2 (48) and 3–4 (48), and 20 controls with mean age 56 years
(55% men), and BMI 26.5. Men and women with OA had higher average
ferritin than those without OA (one way ANOVA, p =0.008; men: 71.06
vs. 40.42ng/ml, p = 0.01; women: 42.57 vs. 32.98ng/ml, p=ns). Ferritin
levels greater than 100ng/ml were observed in 13% of patients with OA,
and in 0% of controls. OA patients had higher frequency of homozygous
HFE gene mutation C282Y/C282Y (2.29%) compared to controls (0%)
and published controls (0.26%, z=3.2). Higher ferritin levels positively
correlated with worsening KL scores in the total OA population (KL
0–2: 38.28 vs. KL 3–4: 62ng/ml, p = 0.02) and in men with OA (KL
0–2 45.03 vs. KL 2–4: 91.69ng/ml, p = 0.04). Also associated with higher
ferritin were increasing age, BMI, and WOMAC pain scores and the
HFE C282Y/C282Y mutation. PGE2 was elevated in OA patients (160.2
vs. 69.3 ng/ml, p < 0.001) and in those with higher ferritin (p = 0.05).
Similarly, COMP fragments was also elevated in OA patients (286.7 vs.
109.9 ng/ml, p = 0.03) and in those with higher ferritin (p = 0.05).
Conclusions: Selected patients with symptomatic knee OA have
increased ferritin compared to controls, as well as an increased incidence
of the C282Y/C282Y HFE gene mutation. Higher levels of ferritin in OA are
